Improving Clinical Target Volume (CTV) Dose Homogeneity and Normal Tissue Maximum Dose for Endoesophageal High-Dose-Rate (HDR) Brachytherapy: One Versus Three HDR Tube Technique

Brachytherapy ◽  
2011 ◽  
Vol 10 ◽  
pp. S70-S71
Author(s):  
John F. Greskovich ◽  
Matt D. Kolar ◽  
John A. Dumot ◽  
Allan Wilkinson
2021 ◽  
Vol 07 (02) ◽  
pp. 085-088
Author(s):  
Hanady Hegazy ◽  
Neamat Hegazy ◽  
Maher Soliman ◽  
Amr Elsaid

AbstractConcurrent chemoradiotherapy is considered the standard treatment for the locally advanced cancer cervix (LACC). Radiotherapy is commonly administered by a three-dimensional conformal radiotherapy (3DCRT) approach followed by brachytherapy (BT). High dose rate (HDR) BT is commonly administered; however, several drawbacks exist including invasive technique, pain, requirement of anesthesia, and operative risks. We assessed the dosimetric difference between the HDR BT and the volumetric modulated arc therapy (VMAT) boost in those patients. Ten patients were selected retrospectively with LACC and all received whole pelvis radiotherapy followed by BT boost of 7 Gy in three fractions. The computed tomography (CT) image was transferred to the Varian system for the VMAT plan while the one with the applicator was transferred to the Sagi planning system and the high-risk clinical target volume (HR-CTV), bladder, rectum, sigmoid, and small bowel were delineate with a margin of 5 mm were added to the CTV to create the planning target volume (PTV). The D90 for the PTV in VMAT boost was lower than received by the HR-CTV in the BT boost. Mean volume of the PTV was higher than that of the HR-CTV. The D2cc was higher in VMAT for bladder, sigmoid, and rectum while the D2cc for the small bowel in BT was higher compared with the VMAT. The VMAT is an option that exists for patients who refuse BT or cannot tolerate it, or in case of nonavailability of BT or a nonworking machine.


Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1425
Author(s):  
Paweł Cisek ◽  
Dariusz Kieszko ◽  
Mateusz Bilski ◽  
Radomir Dębicki ◽  
Ewelina Grywalska ◽  
...  

Background: Eyelid tumors are rare skin cancers, the most common of which is basal cell carcinoma characterized primarily by local growth. In addition to surgery, radiotherapy is among the basic methods of treatment. External beam radiotherapy is associated with the risk of complications within ocular structures, especially the lens. In the case of interstitial brachytherapy, it is possible to administer a high dose to the clinical target volume (CTV), while reducing it in the most sensitive structures. Methods: This paper presents the results of an analysis of 28 patients treated with interstitial high dose rate (HDR) brachytherapy for skin cancers of the upper and lower eyelid; medial and lateral canthus; and the cheek, nose and temples with the infiltration of ocular structures. The patients were treated according to two irradiation schedules: 49 Gy in 14 fractions of 3.5 Gy twice a day for 7 days of treatment, and 45 Gy in 5 Gy fractions twice a day for 5 days. The mean follow-up was 22 months (3–49 months). Results: two patients (6%) had a relapse: a local recurrence within the irradiated area in one of them, and metastases to lymph nodes in the other. The most common early complication was conjunctivitis (74%), and the most common late complication was dry eye syndrome (59%). Conclusions: Interstitial HDR brachytherapy for skin cancers of the upper and lower eyelid; medial and lateral cants; and the cheek, nose and temples with infiltration of ocular structures is a highly effective, short and relatively low burden type of treatment.


Brachytherapy ◽  
2007 ◽  
Vol 6 (2) ◽  
pp. 86
Author(s):  
Michel I. Ghilezan ◽  
J. Vito Antonucci ◽  
Gary S. Gustafson ◽  
Peter Chen ◽  
Michelle Wallace ◽  
...  

Author(s):  
P.J. Anderson ◽  
R.J. Mark ◽  
R.S. Akins ◽  
T.R. Neumann ◽  
S. Gurley ◽  
...  

Brachytherapy ◽  
2006 ◽  
Vol 5 (2) ◽  
pp. 91
Author(s):  
Matthew Biagioli ◽  
B-Chen Wen ◽  
Brandon Patton ◽  
Caroline Hoffman ◽  
Mark Harvey

Author(s):  
Anil Kumar Maurya ◽  
Rajesh Kumar Maurya ◽  
Surendrakumar Dayashankar Maurya ◽  
Radha Kesarwani ◽  
Virendra Singh

ABSTRACTBackground: High dose rate remote after loading brachytherapy machines have seen tremendous advancement both technologically and their clinical applications during the last 25 years. With the introduction of computerized remote after loading machines and computerized planning system, stepping source dosimetry system (SSDS) has become the system of choice making almost all traditional dosimetry systems obsolete. In this study we evaluated the impact of source step size on dosimetry of interstitial implant using parameters of ICRU-58 and various quality indices (QI).Material & Methods: For this study, 10 implant cases which have 3-D CT image based planning were selected. Contouring of clinical target volume and various organs were done following standard guidelines for the same. Plans were optimized to achieve the desired clinical outcome using different source step sizes of 2.5, 5 and 10 mm respectively. Cumulative DVH’s were calculated for the estimation of various ICRU-58 parameters and quality indices.Results and Conclusion: The mean values of the target volumes, minimum target doses, treated volumes, low dose volumes; high dose volumes, overdose volumes, reference volumes, coverage, external volume, relative dose homogeneity, overdose volume and COIN indices have been presented for the source step sizes of 2.5 mm, 5 mm and 10 mm respectively. Among source step sizes used in this study, most favorable clinically acceptable dose distributions & dose homogeneity occurs around step size of 5 mm as predicted by the various parameters of ICRU-58 and dose quality indices. Keywords: Brachytherapy, interstitial implant, source step-size, remote after loading, optimization, quality indices.


2021 ◽  
Vol 1 (3) ◽  
pp. 77-106
Author(s):  
Amir Shahabaz ◽  
Muhammad Afzal

A technique of radiation therapy delivery in which the radioactive sources are placed very close or even inside the target volume is called Brachytherapy (BT). Brachytherapy is a type of radiation therapy. It destroys cancer cells by making it hard for them to multiply. In this technique, a radiation source is placed directly into or near a tumour. High dose-rate brachytherapy is also known as HDR brachytherapy, or temporary brachytherapy. It is a type of internal radiotherapy. HDR was developed to reduce the risk of cancer recurrence while shortening the amount of time it takes to get radiation treatment. HDR also limits the dose of radiation (associated side effects) to surrounding normal tissue. The important benefits of HDR brachytherapy include extremely precise radiation therapy delivered internally, used alone or after surgery to help prevent cancer recurrence, convenient treatments that are usually pain-free, and a reduction in the risk of common short- and long-term side effects. Currently, tumour dose, as well as doses of the surrounding normal structures, can be evaluated accurately, and high-dose-rate brachytherapy enables three-dimensional image guidance. The biological disadvantages of high-dose-rate were overcome by fractional irradiation. In the definitive radiation therapy of cervical cancer, high-dose-rate brachytherapy is most necessary. Most patients feel little discomfort during brachytherapy. There is no residual radioactivity when the treatment is completed. A patient may be able to go home shortly after the procedure, resuming his normal activities with few restrictions. An advantage of brachytherapy is to deliver a high dose to the tumour during treatment and save the surrounding normal tissues. High-dose-rate (HDR) brachytherapy has great promise with respect to proper case selection and delivery technique because it eliminates radiation exposure, can be performed on an outpatient basis and allows short treatment times. Additionally, by varying the dwell time at each dwell position, the use of a single-stepping source allows optimization of dose distribution. As the short treatment times do not allow any time for correction of errors, and mistakes can result in harm to patients, so the treatments must be executed carefully by using HDR brachytherapy. Refinements will occur primarily in the integration of imaging (computed tomography, magnetic resonance imaging, intraoperative ultrasonography) and optimization of dose distribution and it is expected that the use of HDR brachytherapy will greatly expand over the next decade. Various factors in the development of well-controlled randomized trials addressing issues of efficacy, quality of life, toxicity and costs-versus-benefits will ultimately define the role of HDR brachytherapy in the therapeutic armamentarium. Surrounding healthy tissues are not affected by the radiation due to the ability to target radiation therapy at high dose rates directly to the tumour. Treatment to be delivered as an outpatient in as few as one to five sessions is also allowed by this targeted high dose approach. HDR brachytherapy is the most precision radiation therapy, even better than carbon ion therapy. At the time of invasive placement of the radiation source into the tumour area, brachytherapy requires the skills and techniques of radiation oncologists.


Sign in / Sign up

Export Citation Format

Share Document